Raymond James Financial Inc. Lowers Stock Holdings in Danaher Corporation (NYSE:DHR)

Raymond James Financial Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 7.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,576,921 shares of the conglomerate’s stock after selling 127,163 shares during the quarter. Raymond James Financial Inc.’s holdings in Danaher were worth $323,269,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GHP Investment Advisors Inc. boosted its stake in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of Danaher in the 4th quarter valued at about $27,000. Sierra Ocean LLC boosted its stake in shares of Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after buying an additional 76 shares during the period. Smallwood Wealth Investment Management LLC purchased a new position in shares of Danaher in the 1st quarter valued at about $31,000. Finally, Dunhill Financial LLC boosted its stake in shares of Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after buying an additional 67 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DHR. Deutsche Bank Aktiengesellschaft decreased their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Leerink Partners boosted their target price on Danaher from $225.00 to $230.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 23rd. Argus decreased their target price on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. TD Cowen boosted their target price on Danaher from $240.00 to $248.00 and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Trading Up 0.3%

NYSE:DHR opened at $210.84 on Friday. The firm has a market cap of $150.97 billion, a P/E ratio of 44.86, a PEG ratio of 2.94 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock’s 50 day simple moving average is $199.94 and its 200-day simple moving average is $199.71. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.72 earnings per share. Equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.